Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor + ivacaftor in children with cystic fibrosis homozygous for F508del
2015-000543-16Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Lumacaftor + ivacaftor with Placebo (2 arms). Primary endpoint: Absolute change in lung clearance index 2.5. Started May 2015; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-000543-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000543-16.